YDES vs BTBT vs NUVB vs ZLAB vs ZYME

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 15. 3% for Zai Lab Limited (ZLAB). Bit Digital, Inc. (BTBT) offers the better valuation at 9. 8x trailing P/E, making it the more compelling value choice. Analysts rate Bit Digital, Inc. (BTBT) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Zymeworks Inc.

(ZYME) delivered a total return of -13. 3%, compared to -86. 6% for Zai Lab Limited (ZLAB). Over 10 years, the gap is even starker: ZYME returned +83. 8% versus BTBT's -57. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), YD Bio Limited Ordinary Shares (YDES) is the lower-risk stock at 0.

80β versus Bit Digital, Inc. 's 3. 41β — meaning BTBT is approximately 328% more volatile than YDES relative to the S&P 500. On balance sheet safety, YD Bio Limited Ordinary Shares (YDES) carries a lower debt/equity ratio of 0% versus 31% for Zai Lab Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 15. 3% for Zai Lab Limited (ZLAB). On earnings-per-share growth, the picture is similar: Bit Digital, Inc. grew EPS 225. 0% year-over-year, compared to 33. 3% for Zymeworks Inc.. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bit Digital, Inc.

(BTBT) is the more profitable company, earning 17. 3% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 17. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTBT leads at 16. 8% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — ZYME leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NUVB: 156.

2% to $12. 40.

In this comparison, BTBT (0.

3% yield) pays a dividend. YDES, NUVB, ZLAB, ZYME do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, YD Bio Limited Ordinary Shares (YDES) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

80)). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (YDES: -56. 9%, BTBT: -57. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (YDES (Healthcare) and BTBT (Financial Services) and NUVB (Healthcare) and ZLAB (Healthcare) and ZYME (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.